#United States #San Francisco #Securities Fraud #Hagens Berman #ADMA Biologics

Investors of ADMA Biologics, Inc.: Class Action Lawsuit Alert

Overview

Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) are being alerted by the law firm Hagens Berman about a newly filed securities fraud class action lawsuit. This legal action highlights significant concerns regarding the company's financial health and business practices and provides an opportunity for affected shareholders to seek redress.

Details of the Lawsuit

The class action lawsuit, which covers the period from August 9, 2024, to March 25, 2026, alleges that ADMA Biologics misrepresented crucial aspects of its operations, including revenue recognition and inventory distribution. These misrepresentations are thought to have artificially inflated the company’s stock value, misleading investors about the true state of its finances.

Allegations Against ADMA Biologics

The lawsuit accuses the defendants of various unauthorized practices, including:

• - Undisclosed Related Party Transactions: Allegations suggest that ADMA was involved in undisclosed transactions with insiders that could compromise investors' interests.
• - Channel Stuffing: This refers to practices aimed at inflating revenue figures by pushing excess products to distributors, creating a misleadingly optimistic financial outlook.
• - Inadequate Internal Controls: Claims point to the absence of stringent internal checks to ensure accurate financial reporting, raising questions about the integrity of the financial statements issued to investors.

These actions have led to statements made by ADMA being deemed inconsistent with reality, leaving investors in the dark about risk factors affecting their investments.

Market Reactions

The truth about ADMA's financial practices emerged through several significant corrective events, triggering massive sell-offs in the stock. For instance, on March 24, 2026, a report by Culper Research exposed channel stuffing and undisclosed transactions, which resulted in a drastic drop of 31.6% in stock value over just two days. This decline further accelerated following an ADMA press release addressing the report but coinciding with a downgrade from Cantor Fitzgerald, contributing to continued investor mistrust.

Steps for Affected Investors

Investors who have suffered substantial financial losses from their investments in ADMA Biologics should consider participating in the class action lawsuit. The lead plaintiff deadline is set for August 10, 2026, and those interested in joining the lawsuit are encouraged to contact Hagens Berman as soon as possible to share their experiences and losses.
Additionally, anyone with non-public information regarding ADMA may wish to consult the firm's investigation team or consider the U.S. SEC Whistleblower Program, which offers the potential for rewards based on successful recovery in securities fraud cases.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is a prominent law firm specializing in class action lawsuits and shareholder rights. The firm actively advocates for transparency and accountability within corporations, having successfully secured over $2.9 billion in recoveries for various litigations. Their commitment to protecting investors' rights and widening corporate accountability is evident through their extensive practice and resources available for affected shareholders.

For more information regarding the ADMA case or if you believe you have relevant knowledge or were adversely affected by their business practices, reach out to Hagens Berman directly or visit their official website for further inquiries.

• ---

This article serves as a crucial notice for current and former investors of ADMA Biologics. Awareness and information accessibility are vital in navigating complex legal landscapes following potential investment fraud.